Fortelyzin® in comparison with Metalyse® for ST-elevated myocardial infarction: one-year results and clinical outcomes of a multicenter randomized study FRIDOM1
Aim. Evaluate the oneyear results and clinical outcomes of a multicenter randomized clinical trial FRIDOM1.Material and methods. The study FRIDOM1 was conducted in 11 clinical centers of the Russian Federation in the period 20142016. The study included 382 patients with acute STelevated myocardi...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2018-12-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/3050 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849341544192016384 |
|---|---|
| author | V. A. Markov D. V. Duplyakov S. L. Konstantinov G. V. Klein S. B. Aksentev D. Yu. Platonov E. V. Vyshlov E. A. Ponomarev R. M. Rabinovich E. L. Makarov E. V. Kulibaba D. S. Yunevich O. V. Kritskaia E. A. Baranov O. B. Talibov E. A. Gerasimets |
| author_facet | V. A. Markov D. V. Duplyakov S. L. Konstantinov G. V. Klein S. B. Aksentev D. Yu. Platonov E. V. Vyshlov E. A. Ponomarev R. M. Rabinovich E. L. Makarov E. V. Kulibaba D. S. Yunevich O. V. Kritskaia E. A. Baranov O. B. Talibov E. A. Gerasimets |
| author_sort | V. A. Markov |
| collection | DOAJ |
| description | Aim. Evaluate the oneyear results and clinical outcomes of a multicenter randomized clinical trial FRIDOM1.Material and methods. The study FRIDOM1 was conducted in 11 clinical centers of the Russian Federation in the period 20142016. The study included 382 patients with acute STelevated myocardial infarction (STEMI), who were randomly divided into the Fortelyzin® and Metalyse®. Thrombolysis was accompanied by anticoagulant and dual antiplatelet therapy followed by percutaneous coronary intervention (PCI). Oneyear patient status, allcause mortality, including cardiovascular diseases (CVD), hospitalization, and oneyear survival were assessed by telephone contact.Results. The oneyear patient status was determined in 186 out of 191 (97,4%) in the Fortelyzin® group and in 185 out of 191 (96,9%) patients in the Metalyse® group. Oneyear allcause mortality was 5,9% and 6,5% in the Fortelyzin® and Metalyse® groups, respectively (p=0,83; OR 0,91; 95% CI — 0,421,98). Oneyear mortality from CVD in the Fortelyzin® group is 5,4%, in the Metalyse® group — 6,5% (p=0,67; OR 0,83; 95% CI — 0,371,83). Allcause mortality between 30 days and 1 year in the Fortelyzin® group was in 2,2% of patients, CVD — in 1,6%, in the group of Metalise® mortality was in 2,7% of patients (all — CVD). Oneyear survival was 94,1% and 93,5% in the Fortelyzin® and Metalyse® groups, respectively.Conclusion. The oneyear results of the FRIDOM1 study showed the efficacy and safety of a single bolus administration of Fortelyzin® as part of a pharmacoinvasive strategy for treating patients with STEMI, as well as clinical outcomes that are comparable with Metalyse®, including high survival rates and low CVD mortality. |
| format | Article |
| id | doaj-art-d356e98be2464985907eb248a4d50606 |
| institution | Kabale University |
| issn | 1560-4071 2618-7620 |
| language | Russian |
| publishDate | 2018-12-01 |
| publisher | «FIRMA «SILICEA» LLC |
| record_format | Article |
| series | Российский кардиологический журнал |
| spelling | doaj-art-d356e98be2464985907eb248a4d506062025-08-20T03:43:36Zrus«FIRMA «SILICEA» LLCРоссийский кардиологический журнал1560-40712618-76202018-12-0101111011610.15829/1560-4071-2018-11-110-1162523Fortelyzin® in comparison with Metalyse® for ST-elevated myocardial infarction: one-year results and clinical outcomes of a multicenter randomized study FRIDOM1V. A. Markov0D. V. Duplyakov1S. L. Konstantinov2G. V. Klein3S. B. Aksentev4D. Yu. Platonov5E. V. Vyshlov6E. A. Ponomarev7R. M. Rabinovich8E. L. Makarov9E. V. Kulibaba10D. S. Yunevich11O. V. Kritskaia12E. A. Baranov13O. B. Talibov14E. A. Gerasimets15Tomsk National Research Medical Center of the Russian Academy of Sciences; Siberian State Medical University.Samara Regional Clinical Cardiology Dispensary.Sant Ioasaf Belgorod Regional Clinical Hospital.P.A. Bayandin Murmansk Regional Clinical Hospital.Ryazan Regional Clinical Hospital.Tver Regional Clinical Hospital.Tomsk National Research Medical Center of the Russian Academy of Sciences.Volgograd City Emergency Clinical Hospital № 25.Tver Regional Clinical Hospital.Nizhny Novgorod Emergency Care Station.Vladimir City Hospital № 4.Ryazan Regional Clinical Hospital.Vladimir City Hospital № 4.Nizhny Novgorod City Hospital № 5.Moscow State University of Medicine and Dentistry.The Peoples’ Friendship University of Russia.Aim. Evaluate the oneyear results and clinical outcomes of a multicenter randomized clinical trial FRIDOM1.Material and methods. The study FRIDOM1 was conducted in 11 clinical centers of the Russian Federation in the period 20142016. The study included 382 patients with acute STelevated myocardial infarction (STEMI), who were randomly divided into the Fortelyzin® and Metalyse®. Thrombolysis was accompanied by anticoagulant and dual antiplatelet therapy followed by percutaneous coronary intervention (PCI). Oneyear patient status, allcause mortality, including cardiovascular diseases (CVD), hospitalization, and oneyear survival were assessed by telephone contact.Results. The oneyear patient status was determined in 186 out of 191 (97,4%) in the Fortelyzin® group and in 185 out of 191 (96,9%) patients in the Metalyse® group. Oneyear allcause mortality was 5,9% and 6,5% in the Fortelyzin® and Metalyse® groups, respectively (p=0,83; OR 0,91; 95% CI — 0,421,98). Oneyear mortality from CVD in the Fortelyzin® group is 5,4%, in the Metalyse® group — 6,5% (p=0,67; OR 0,83; 95% CI — 0,371,83). Allcause mortality between 30 days and 1 year in the Fortelyzin® group was in 2,2% of patients, CVD — in 1,6%, in the group of Metalise® mortality was in 2,7% of patients (all — CVD). Oneyear survival was 94,1% and 93,5% in the Fortelyzin® and Metalyse® groups, respectively.Conclusion. The oneyear results of the FRIDOM1 study showed the efficacy and safety of a single bolus administration of Fortelyzin® as part of a pharmacoinvasive strategy for treating patients with STEMI, as well as clinical outcomes that are comparable with Metalyse®, including high survival rates and low CVD mortality.https://russjcardiol.elpub.ru/jour/article/view/3050stelevated myocardial infarctionfortelyzin®metalyse®pharmacoinvasive strategyoneyear results |
| spellingShingle | V. A. Markov D. V. Duplyakov S. L. Konstantinov G. V. Klein S. B. Aksentev D. Yu. Platonov E. V. Vyshlov E. A. Ponomarev R. M. Rabinovich E. L. Makarov E. V. Kulibaba D. S. Yunevich O. V. Kritskaia E. A. Baranov O. B. Talibov E. A. Gerasimets Fortelyzin® in comparison with Metalyse® for ST-elevated myocardial infarction: one-year results and clinical outcomes of a multicenter randomized study FRIDOM1 Российский кардиологический журнал stelevated myocardial infarction fortelyzin® metalyse® pharmacoinvasive strategy oneyear results |
| title | Fortelyzin® in comparison with Metalyse® for ST-elevated myocardial infarction: one-year results and clinical outcomes of a multicenter randomized study FRIDOM1 |
| title_full | Fortelyzin® in comparison with Metalyse® for ST-elevated myocardial infarction: one-year results and clinical outcomes of a multicenter randomized study FRIDOM1 |
| title_fullStr | Fortelyzin® in comparison with Metalyse® for ST-elevated myocardial infarction: one-year results and clinical outcomes of a multicenter randomized study FRIDOM1 |
| title_full_unstemmed | Fortelyzin® in comparison with Metalyse® for ST-elevated myocardial infarction: one-year results and clinical outcomes of a multicenter randomized study FRIDOM1 |
| title_short | Fortelyzin® in comparison with Metalyse® for ST-elevated myocardial infarction: one-year results and clinical outcomes of a multicenter randomized study FRIDOM1 |
| title_sort | fortelyzin r in comparison with metalyse r for st elevated myocardial infarction one year results and clinical outcomes of a multicenter randomized study fridom1 |
| topic | stelevated myocardial infarction fortelyzin® metalyse® pharmacoinvasive strategy oneyear results |
| url | https://russjcardiol.elpub.ru/jour/article/view/3050 |
| work_keys_str_mv | AT vamarkov fortelyzinincomparisonwithmetalyseforstelevatedmyocardialinfarctiononeyearresultsandclinicaloutcomesofamulticenterrandomizedstudyfridom1 AT dvduplyakov fortelyzinincomparisonwithmetalyseforstelevatedmyocardialinfarctiononeyearresultsandclinicaloutcomesofamulticenterrandomizedstudyfridom1 AT slkonstantinov fortelyzinincomparisonwithmetalyseforstelevatedmyocardialinfarctiononeyearresultsandclinicaloutcomesofamulticenterrandomizedstudyfridom1 AT gvklein fortelyzinincomparisonwithmetalyseforstelevatedmyocardialinfarctiononeyearresultsandclinicaloutcomesofamulticenterrandomizedstudyfridom1 AT sbaksentev fortelyzinincomparisonwithmetalyseforstelevatedmyocardialinfarctiononeyearresultsandclinicaloutcomesofamulticenterrandomizedstudyfridom1 AT dyuplatonov fortelyzinincomparisonwithmetalyseforstelevatedmyocardialinfarctiononeyearresultsandclinicaloutcomesofamulticenterrandomizedstudyfridom1 AT evvyshlov fortelyzinincomparisonwithmetalyseforstelevatedmyocardialinfarctiononeyearresultsandclinicaloutcomesofamulticenterrandomizedstudyfridom1 AT eaponomarev fortelyzinincomparisonwithmetalyseforstelevatedmyocardialinfarctiononeyearresultsandclinicaloutcomesofamulticenterrandomizedstudyfridom1 AT rmrabinovich fortelyzinincomparisonwithmetalyseforstelevatedmyocardialinfarctiononeyearresultsandclinicaloutcomesofamulticenterrandomizedstudyfridom1 AT elmakarov fortelyzinincomparisonwithmetalyseforstelevatedmyocardialinfarctiononeyearresultsandclinicaloutcomesofamulticenterrandomizedstudyfridom1 AT evkulibaba fortelyzinincomparisonwithmetalyseforstelevatedmyocardialinfarctiononeyearresultsandclinicaloutcomesofamulticenterrandomizedstudyfridom1 AT dsyunevich fortelyzinincomparisonwithmetalyseforstelevatedmyocardialinfarctiononeyearresultsandclinicaloutcomesofamulticenterrandomizedstudyfridom1 AT ovkritskaia fortelyzinincomparisonwithmetalyseforstelevatedmyocardialinfarctiononeyearresultsandclinicaloutcomesofamulticenterrandomizedstudyfridom1 AT eabaranov fortelyzinincomparisonwithmetalyseforstelevatedmyocardialinfarctiononeyearresultsandclinicaloutcomesofamulticenterrandomizedstudyfridom1 AT obtalibov fortelyzinincomparisonwithmetalyseforstelevatedmyocardialinfarctiononeyearresultsandclinicaloutcomesofamulticenterrandomizedstudyfridom1 AT eagerasimets fortelyzinincomparisonwithmetalyseforstelevatedmyocardialinfarctiononeyearresultsandclinicaloutcomesofamulticenterrandomizedstudyfridom1 |